THORChain co-founder Chad Barraford explained that while the protocol can block laundering by reaching a two-thirds validator consensus, quickly stopping hackers like those involved in the Bitget $387.5 million hack is difficult. Coordinating validators takes days, during which attackers can move stolen funds across addresses. Although THORChain has mechanisms to pause trading temporarily, broad halts affect legitimate users and require consensus, slowing responses. Barraford noted that faster intervention would need redesigning the protocol for more centralized control, but validators could theoretically block illicit transactions if enough agree. The debate highlights the trade-off between decentralization and rapid action against theft in crypto protocols.
The THORChain co-founder discussed challenges in quickly stopping hackers, highlighting the trade-off between decentralization and rapid intervention. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 06, 2026 23:03 WIB: out of 50 major cryptocurrencies, 25 rose and 24 fell. Notable movers include THETA with a 1-day change of +2.63% and 100% sell order activity, CAKE down by -2.62% with 55% sell orders, and SNX up by +2.47% with 99% buy orders.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
